Presage Biosciences Announces First Patient in Clinical Trial of CIVO(TM ... Wall Street Journal The trial will enroll up to 12 patients with either newly diagnosed lymphomas who have not yet received treatment or relapsed lymphoma previously treated with one or more agents in the R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, ... |
